Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review by Blank, P R et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Cost effectiveness of cytotoxic and targeted therapy for
metastatic breast cancer: a critical and systematic review
Blank, P R; Dedes, K J; Szucs, T D
Blank, P R; Dedes, K J; Szucs, T D (2010). Cost effectiveness of cytotoxic and targeted therapy for metastatic
breast cancer: a critical and systematic review. PharmacoEconomics, 28(8):629-647.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
PharmacoEconomics 2010, 28(8):629-647.
Blank, P R; Dedes, K J; Szucs, T D (2010). Cost effectiveness of cytotoxic and targeted therapy for metastatic
breast cancer: a critical and systematic review. PharmacoEconomics, 28(8):629-647.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
PharmacoEconomics 2010, 28(8):629-647.
1 
 
Cost-Effectiveness of Cytotoxic and Targeted 
Therapy for Metastatic Breast Cancer: A Critical and 
Systematic Review 
  
 
 
Patricia R. Blank1*, Konstantin J. Dedes2 and Thomas D. Szucs1 
1Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland 
2Department of Gynecology, University Hospital of Zurich, Zurich, Switzerland 
  
  
  
Running title: Cost Effectiveness of Metastatic Breast Cancer Therapies 
  
  
  
  
  
  
Correspondence: Patricia R.Blank, Institute of Social and Preventive Medicine, University of Zurich, 
Hirschengraben 84, 8001 Zurich, Switzerland, Phone +41(0)44’634’4681, Fax +41(0)44’634’4708, 
Email: patricia.blank@ifspm.uzh.ch  
 
 
2 
 
Table of contents 
Table of contents ................................................................................................................... 2 
Abstract ................................................................................................................................. 3 
Introduction ........................................................................................................................... 4 
Objective ............................................................................................................................... 5 
Methods ................................................................................................................................ 5 
Data source and selection.................................................................................................. 5 
Results .................................................................................................................................. 6 
Overview of included papers .............................................................................................. 6 
Cost-effectiveness studies of conventional chemotherapies .............................................. 7 
Cost-effectiveness studies of targeted therapies ................................................................ 9 
Quality assessment of key modeling issues ......................................................................12 
Input parameters ...........................................................................................................12 
Sensitivity analyses .......................................................................................................12 
Perspective of the analysis ............................................................................................12 
Influence of the cost-effectiveness ratio .........................................................................13 
Comparability of different studies ..................................................................................13 
Role of financial funding ................................................................................................14 
Discussion ............................................................................................................................14 
Conclusion ...........................................................................................................................16 
Acknowledgment ..............................................................................................................17 
Conflict of interest .............................................................................................................17 
References ...........................................................................................................................18 
Figure legend .......................................................................................................................22 
Tables ..................................................................................................................................23 
 
 
3 
 
Abstract 
Breast cancer is the leading cancer type diagnosed among females in Western countries. Despite 
great advantages in cancer therapies, many of these patients develop a non-curable metastases. The 
objective of cancer treatment is mainly to control symptoms and to prolong survival. The selection of 
the optimal chemotherapeutic regimen is affected by performance status, tumor biology, site and 
extent of the disease and the exposure to prior therapies. Recent developments in new kind of cancer 
drugs contributed not only to an immense progress in clinical outcomes, but also raised treatment 
related health costs dramatically. Cost-effectiveness analysis is a type of economic evaluation that 
refers to both costs and health outcomes of alternative intervention strategies in a systematic way. In 
this review, a systematic literature search was performed and the evidence on the cost-effectiveness 
of conventional chemotherapy and targeted therapy for metastatic breast cancer was explored.  
Cost-effectiveness/-utility analysis of treatment regimens for metastatic breast cancer patients were 
identified using literature and reference searches (MEDLINE). Published reports on conventional and 
targeted cancer therapies were scrutinized and incremental cost-effectiveness ratios (ICERs) were 
abstracted. Furthermore, the quality of reporting, as well as methodological and modeling issues were 
extensively discussed. 
From full-text article reviews, six cost-effectiveness analyses on conventional and seven studies on 
targeted therapies were included. Eight analyses were conducted in European countries, three in the 
United States and two in Canada. Primarily, the economic models were based in clinical trial data 
(69%). Results from sensitivity analyses and perspectives were reported by all studies. Discount rates 
was mentioned in five articles (39%). The methods of reporting costs and effects varied considerably.  
Considerable differences in trial designs across conventional chemotherapies raise difficulties to 
compare those analyses.  
The results from the pharmaco-economic studies came to different conclusions. The actual clinical 
evidence does not suggest one conventional chemotherapy regimen as superior. Studies on cytotoxic 
agents showed mainly favorable cost-effectiveness ratios. Targeted therapies indicated both favorable 
and non-favorable ratios. Currently, trastuzumab is the only anti-body based targeted therapy which is 
established in the clinic for the metastatic setting.  
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Introduction  
Breast Cancer is the most common cancer diagnosed in women in Western countries. About 25-40% 
patients develop a metastasis in the course of their illness [1, 2]. Since metastatic breast cancer is not 
curable, one of the main goals of treating these patients with metastatic or recurrent breast cancer is 
to provide palliation of symptoms and the maintenance or improvement of quality of life. The 
prolongation of life expectancy is a secondary goal. The armamentarium for palliative treatment 
contains potent endocrine treatments for the hormone receptor positive breast cancers, 
bisphosphonates for the subset of patients with bone disease, targeted therapy for, so far, mainly the 
subgroup of HER2 positive patents and finally conventional cytotoxic chemotherapy.  
Conventional chemotherapeutics do not act on the diverse signaling pathways which help the tumor 
progressing but rather target dividing cells in general and are therefore associated with a wide range 
of side effects. For breast cancer in particular conventional chemotherapy for metastatic disease is 
usually administered after the failure of endocrine treatment. The fact that nowadays a high 
percentage of patients with early breast cancer receive adjuvant combination chemotherapy affects 
the decision of the regimen administered for recurrent or metastatic disease. Patients recurring after 
anthracyclines in the adjuvant setting usually receive a taxane-containing regimen, whereas patients 
after adjuvant taxanes usually receive an anthracycline-based regimen. 
Targeted drugs however exploit specific molecular characteristics of the tumor and do usually not 
affect cells without that specific target. Several classes of antibody-based targeted therapies have 
raised hope in the treatment of breast cancer[3]. Trastuzumab (Herceptin®, Roche Pharma, 
Switzerland), a monoclonal antibody targeted to the human epidermal growth factor receptor 2 (HER-
2) is currently routinely used in both the adjuvant and metastatic settings for patients with HER-2-
positive tumors[4]. The efficacy and safety of trastuzumab as first-line treatment in metastatic breast 
cancer patients has been demonstrated in several randomized controlled trials [5-8]. However, 
trastuzumab is limited to 15-25% of breast cancer patients overexpressing the protein or amplifying 
the HER-2 oncogene [9-11]. Lapatinib is a oral available dual tyrosine kinase inhibitor of the HER-2 
kinase and has been approved in some countries for metastatic HER-2 patients progressing under 
trastuzumab treatment or as first line oral treatment in combination with endocrine therapy [12]. 
Pertuzumab, a further monoclonal antibody binding a different epitope on HER-2 than trastuzumab is 
under clinical assessment. This agent has been developed for breast cancer patients whether 
overexpressing HER-2 or not [13, 14]. Bevacizumab (Avastin®, Roche Pharma, Switzerland) is a 
monoclonal antibody directed against vascular endothelial growth factor-A. Given its antiangiogenic 
properties, it is being evaluated in the metastatic setting, and is showing promising results [15]. 
Bevacizumab has been approved in a combination therapy for metastatic breast cancer with a 
negative HER-2 status [16].  
The complex economics of new oncology drug developments are an important area of research [17]. 
However, the progress in the development of new cancer treatments are connected to costs, namely 
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treatment-related expenses and effects on quality of life. Especially expensive drugs have to 
demonstrate relevant improvements in regard to length of life, quality of life or if there is no other 
alternative available to be regarded as justified [18, 19]. In response to the growing concern about the 
costs of pharmaceutical products, pharmacoeconomic studies investigate the impact of new drugs or 
interventions on the patient's quality of life and the health care outcome through, e.g. cost-
effectiveness studies. Economic analyses ideally cover clinical and economic outcomes achieved in 
randomized controlled trials. Such models play an important role in the decisions of policy makers in 
terms of coverage and reimbursement of the product. 
According to the International Society for Pharmacoeconomics and Outcome Research (ISPOR)[20], 
economic studies would require a wide-ranging sensitivity analysis, the inclusion of the adequate time 
horizon and discount rate, the statement of the related perspective and the inclusion of a systematic 
and extensive literature review. However, the present review aimed at assessing the cost 
effectiveness of cytotoxic and targeted chemotherapeutic regimens for metastatic breast cancer in the 
published literature. Besides the extensive discussion of all studies, we placed particular emphasis on 
the key drivers of cost effectiveness of the various treatment agents.  
Objective 
The aim of this review was to identify published, original cost-effectiveness analyses of chemotherapy 
and targeted non-chemotherapy regimens for metastatic breast cancer presented as cost per life year 
gained (LYG) or quality adjusted life year (QALY) and to compare and summarize findings. The quality 
of reporting was critically assessed.  
Methods  
Data source and selection 
MEDLINE and PubMed were searched systematically for all original cost-effectiveness analysis 
published between 2000 and 2009. Given that the field of targeted therapies is new, we included 
studies published only from the year 2000 onwards to ensure a comparable study population in both 
conventional and targeted therapeutic setting. The search was conducted with the text keywords cost, 
effectiveness, utility, breast, cancer metastatic, advanced. A total of 671 articles were recognized in 
the initial literature search. Title and abstracts were screened by two independent reviewers to 
determine whether the reports were an original health economic study. Studies considered important 
after the first screening cycle were evaluated at full-text. For literature saturation, reference lists were 
explored for relevant reports. Studies were included if they were reports on cost-effectiveness or cost-
utility reports of metastatic breast cancer therapies. Descriptive cost studies, posters, editorials, 
publications not showing primary data or reports written in other languages than English were 
excluded. Cost-effectiveness analyses describing primary the health economic impact of hormonal 
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therapies or predictive testing in targeted non-chemotherapy settings were not taken into account. 
Figure 1 outlines how the final sample size was reached.  
Detailed information from the reports was abstracted by a pre-specified list. A standardized extraction 
form was used to gather the following issues from the studies: characteristics of the study (study 
design, population, perspective), the type and outcome of the economic analysis, the key aspects 
(cancer treatment and comparator strategy, clinical outcome, costs and discount rate) and parameters 
of the sensitivity analysis (if available). For the base-case analysis, incremental cost-effectiveness 
ratios (ICERs) were reported. Studies were grouped into cost-effectiveness analyses addressing either 
conventional chemotherapy or targeted regimens. Particular emphasis on the key drivers of cost 
effectiveness of the various chemotherapy and non-chemotherapy regimens was given. As year of 
reference, the reported monetary year or the year of publication was used. Costs are shown in US 
Dollars ($) (1 Euro (€) ≅ $1.47; 1 GBP (£) ≅ $1.74; 1 CAD ≅ $1).  
Results  
Overview of included papers  
The studies included were focused on breast cancer patients in a metastatic disease state. Outcome 
measures were given in either quality adjusted life year (QALY) (7/13) or in life year gained (LYG) 
(6/13). Eight analyses were conducted in European countries (France, Greek, Norway, Switzerland 
United Kingdom), three in the United States and two in Canada. Only one article was published in a 
pharmaeconomic and outcome research journal, whereas the remaining articles were published in 
oncology journals. The funding source was mentioned by nine studies (69%).  
The methodologies used varied considerably. The studies included were all using model-based 
analyses for their calculations. Three reports mentioned in their articles that Markov-models have been 
established, whereas only two clearly described the model. The remaining studies used other 
economic models. Data included derived primarily from randomized controlled trial data (9/13). Two 
studies were based on cancer registry and medical record information, respectively. One study was 
conducted with data from an open controlled prospective study and one article was adapted from 
published literature. The studies were simulated from a healthcare payer (10/13), a hospital (1/13) or a 
societal (2/13) perspective. A discount rate of 3% (3/13), 3.5% (1/13) or 5% (1/13) was applied. 
Sensitivity analyses were conducted mainly for costs and effects. The economic analyses based on 
conventional chemotherapies were all considered cost-effective by the authors except one study with 
ixabepilone. In the studies of targeted non-chemotherapeutic agents, authors concluded the 
monoclonal anti-body treatment as cost-effective (3/7), not cost-effective (3/7) or gave no clear 
statement (1/7).  
The summary of cost-effectiveness results of conventional and targeted therapies is given in table 1 
and 2, respectively.  
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Cost-effectiveness studies of conventional chemotherapies  
Maniadakis et al analyzed the cost-effectiveness of three taxane-based regimens which are 
administered as 1st line chemotherapy in patients with metastatic breast cancer that have already 
received anthracyclines in the adjuvant setting [21]. This economic analysis, that was conducted from 
the perspective of the Greek national health system, was based on the randomized phase III trial 
comparing carboplatin and paclitaxel to paclitaxel weekly and to docetaxel and gemcitabine[22]. The 
comparator was carboplatin (area under the curve (AUC) of 6) and paclitaxel (175 mg/m2) 
administered every three weeks for six cycles. Paclitaxel (80 mg/m2) at weekly administration for 12 
weeks and docetaxel (75 mg/m2) combined with gemcitabine (1000 mg/m2) were the two other arms. 
The paclitaxel weekly arm appeared to be the most preferable choice among the three regimens as it 
prolonged the overall survival more than the other combinations without being associated with higher 
side effects. The quality of life was similar in all three arms. Gemcitabine with docetaxel incurred the 
lowest total costs per patients (19,343€; $28434) but proved to be less effective than the two paclitaxel 
containing regimens and was causing more sever myelotoxicity and mucositis. Paclitaxel with 
carboplatin every three weeks cost about the same amount per patients as paclitaxel weekly (20,498€ 
vs. 20,578€; $30,132 vs. $30,250) but was significantly less effective. These results remained fairly 
constant in sensitivity analyses. 
Vu et al compared the cost-effectiveness of docetaxel (100 mg/m2) to paclitaxel (175 mg/m2) both 
administered every three weeks [23]. The analysis was conducted from the perspective of the 
Canadian health care system. The clinical data, in contrast to many other cost-effectiveness studies, 
was not based on a clinical trial but was derived from a provincial cancer registry. The overall survival 
in the docetaxel-treated group was significantly higher than among patients treated with paclitaxel 
(10.9 vs. 8.3 months). This benefit was comparable to the results of a randomized trial comparing both 
agents [24]. The costs per patient were substantially higher in the docetaxel group (9,441 CAD vs 
2,944 CAD; $9,441 vs. $2,944) that was attributed to the higher acquisition costs of docetaxel. The 
cost effectiveness ratio was 30,337 CAD ($30,337) per life year (LYG) gained for docetaxel versus 
paclitaxel.  
Benedict et al compared the same regimens for the UK health care system but used clinical data from 
a randomized controlled trial [25]. In contrast to the Vu et al study, Benedict et al included quality of life 
data retrieved from the literature. Furthermore, the authors indirectly included two additional regimens 
(Pac weekly and nabPac every 3 weeks) by including data from other randomized controlled trial to 
the above mentioned one. However, for paclitaxel weekly, not the best available evidence was 
included[26] but instead two abstracts from meeting proceedings. In the model, the hazard ratios of 
docetaxel, paclitaxel weekly and Nab-paclitaxel every 3 weeks compared to paclitaxel every 3 weeks 
were applied to the baseline hazard with paclitaxel very 3 weeks to model the progression-free and 
overall-survival curves. Out of them the proportion of patients in each of the three health states (no 
progression, progression, death) was calculated at each time point for each treatment.  
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The relative difference between the mean costs per patient in the docetaxel group vs. the paclitaxel 
group was smaller than in the population based analysis of Vu for Canada. Furthermore, the clinical 
benefit derived from a randomized clinical trial was higher than in the Canadian study, proving that 
data from randomized controlled trials usually are not always one to one reproducible in clinical 
practice. The cost-effectiveness ratio was found to be 4500£ to 14500 £ ($7,800 to $25,230) per 
QALY, what is regarded as acceptable for the health care system of the United Kingdom.  
Verma et al compared the costs of adding capecitabine to docetaxel from the perspective of the 
Canadian health care system by combining data from a randomized controlled trial [27] with a 
population based model[28]. The comparator was docetaxel (100 mg/m2) every three weeks. The 
study arm was docetaxel (75 mg/m2) combined with daily oral capecitabine (2,500 mg/m2). The 
randomized clinical trial,showed survival benefit of three months (14.5 v 11.5 months) for the 
combination treatment. This benefit, however, was accompanied with increased toxicity (grade 3 
events: 71% vs 49%), whereas grade 4 events were slightly higher in the monotherapy arm (31% v 
25%). Verma et al conducted a analysis The incremental costs for the combination treatment were 
resulted in a cost-effectiveness ratio of 3,691 CAD ($3,691). Unfortunately, this analysis did not 
account for quality of life.  
Recently, a new nanoparticle albumin-bound formulation of paclitaxel (nab-paclitaxel) was developed 
to improve efficacy and overcome the toxicity associated with the taxanes[29]. The efficacy and safety 
of nab-paclitaxel in the first- and second-line treatment of metastatic breast cancer (MBC) were 
demonstrated in a large randomized trial with paclitaxel serving as the control arm. In that study, nab-
paclitaxel was statistically superior to paclitaxel in terms of objective tumor (33 vs. 19%; P = 0.001) 
and progression free survival (23 vs. 16.9 weeks; P = 0.006)[30]. There was also a trend in favour of 
nab-paclitaxel in overall survival (OS), but it did not reach statistical significance (median = 65.0 vs. 
55.7 weeks; P = 0.37). Patients randomized to the nab-paclitaxel arm had a lower incidence of 
neutropenia but higher grade of sensory neuropathy. In another trial, different dosages of nab-
paclitaxel were compared to the other taxane, docetaxel. The trial compared two weekly (100 and 150 
mg/m2) and an every 3 week (300 mg/m2 q3w) schedule of nab-paclitaxel to docetaxel [30]. Nab-
paclitaxel 150 mg/m2 weekly demonstrated significantly longer progression-free survival (PFS) than 
docetaxel by both independent radiologist assessment (12.9 v 7.5 months, respectively; P = .0065) 
and investigator assessment (14.6 v 7.8 months, respectively; P = .012). Based on these data, that 
included only progression free survival data and no overall survival data, Dranitsaris et al conducted 
an economic evaluation from the perspective of the United Kingdom health care system[31]. Nab-
paclitaxel 150 mg/m2 weekly was associated with the highest cost per patient (£27,222; $47,366) due 
to the acquisition cost and due to costs for supportive care (growth factors, blood transfusions, 
antibiotics and antiemetics). The docetaxel arm was the less expensive treatment arm with £12,923 
($22,486) mean cost per patient. The incremental 5.4 progression free months gained by nab-
paclitaxel 150 mg/m2 compared to docetaxel resulted in a ratio of £31,800 ($55,332) per progression 
free year gained. Quality of life was not considered in this cost-effectiveness analysis. The authors 
concluded that nab-paclitaxel can be considered a reasonable alternative to docetaxel as first-line 
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chemotherapy for MBC and if considering the favorable side-effect profile of nab-paclitaxel the 
inclusion of quality of life and utility benefits would further improve its economic profile.  
Finally, Reed et al analyzed the cost-effectiveness of adding ixabepilone the capecitabine as a third 
line chemotherapy after progression under anthracyclines and taxanes from the perspective of the US 
health care system[32]. The results of this study have to be cautiously compared to the other analysis 
as the underlying patient population has experienced recurrence or progression despite treatments 
with anthracyclines and taxanes, which is associated with poorer response to any chemotherapy and 
poorer survival expectation as such. Clinical data was extracted from a randomized controlled trial 
from which quality of life results were also available and incorporated. The addition of ixabepilone 
prolonged the overall survival by 32 quality adjusted days. The incremental costs for the combination 
therapy amounted at around 30,000$ which results in a cost-effectiveness ratio of $359,000 per 
QALY. The authors concluded that this ratio is higher than for other new treatments in metastatic 
breast cancer.  
Cost-effectiveness studies of targeted therapies  
Norum et al described a model-based cost-effectiveness analysis in MBC patients which included data 
on efficacy of trastuzumab, tolerability, gain in survival, drug charges and production gain or loss from 
a third payer perspective[33]. Based on data presented at a breast cancer conference and Medline 
search, they assessed life years gained and according costs in patients treated with standard 
chemotherapy (docetaxel, anthracycline plus cyclophosphamide or paclitaxel) compared to the 
therapy with addition of trastuzumab (4mg/kg i.v. initial dose, 2mg/kg i.v. weekly dose). Direct costs 
contained drug costs, the assessment of HER-2 status, hospitalization and outpatient clinic costs. 
Costs for the chemotherapeutic agents were assumed to be similar, hence, this factor was not 
incorporated in the model. No indirect costs were included. The incremental survival time with 
trastuzumab was between 0.3 and 0.7 years compared to standard therapy. Drug costs (89% of 
overall costs) and the prolonged treatment in the outpatient clinic (8% of overall costs) were the key 
factors driving costs in the trastuzumab group. Depending on survival gain and discount rate applied, 
incremental cost-effectiveness ranged from €69,212 to €162,417 ($101,742 to $238,753) per LYG. 
The reduction of drug costs and the additional improvement of survival significantly mainly influenced 
the base case results in sensitivity analyses. The authors came to the conclusion that the costs of 
administering trastuzumab to metastatic breast cancer patients for the gain of one year of life are 
considerable high.  
The cost-effectiveness study of trastuzumab published by Perez-Ellis et al was based on a 
retrospective analysis of medical files and according cost data of HER-2 positive patients treated for 
first metastatic progression[34]. Trastuzumab administration was given as single agent or in 
combination with chemotherapy (taxanes). The uptake of trastuzumab was limited to one year or until 
disease progression (standard schedule: 4mg/kg i.v. initial dose, 2mg/kg i.v. weekly dose). Control 
patients received standard treatment (taxanes and/or anthracycline based chemotherapy). Treatment 
costs for the trastuzumab and the no-trastuzumab group were based on hospital direct costs (inpatient 
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hospitalization stay, drug costs, imagery test etc). Costs for predictive testing of HER-2 status were 
omitted from the analysis. Data on quality of life was not taken into consideration. In terms of overall 
survival, the T group showed superior results (37 months vs. 19 months in the Non-T group; p<0.001). 
The per-patient costs in the T-group were considerably higher than in the non-trastuzumab group 
(€39,607 ($58,222) vs. €12,795 ($18,809), respectively). Main cost drivers were the price of 
trastuzumab (40% of the total costs in trastuzumab group) and the length of hospitalization (60% of 
total costs in no-trastuzumab group). Of note, hospital room costs and the number of imagery test 
were substantially increased in the trastuzumab group. The incremental cost effectiveness ratio 
assessed by the bootstrapping method was considered as cost-effective (€27,492/LYG; 
$40,413/LYG). Sensitivity analyses were performed under several assumptions in regard to 
trastuzumab unit costs and hospitalization costs. The according ICER ranged from €8,000 ($11,760) 
to €20,000 ($29,400) per additional life year saved.  
Poncet and colleagues evaluated the economic impact of a 3-weekly dosage schedule of trastuzumab 
in a open controlled prospective study[35]. Costs and effects of patients receiving a combination 
therapy of trastuzumab and paclitaxel (trastuzumab+ paclitaxel; 3-weekly schedule of trastuzumab: 
4mg/kg initial dose, 2mg/kg i.v.) or control therapy (any chemotherapy without trastuzumab) were 
evaluated. According to the medical files of those patients, all costs generated from the hospital were 
included in the analysis (overall care costs, drug costs, immunohistochemical tumor analysis, hospital 
stay, etc). Effectiveness was assessed in terms of overall and progression free survival. The 1-year 
overall survival rate showed a significant difference between comparator and control group (0.85 vs. 
0.47, respectively; p=0.007). The 1-year progression free survival was 60% in the trastuzumab+ 
paclitaxel arm and 42% in the control arm, without a statistical significance. The mean cost-
effectiveness ratio was estimated with the incremental overall survival (+1.43 years) and incremental 
overall costs (+21,980€; +$32,311) yielding an ICER of 15,370€ ($22594) per additional saved year of 
life gained in the trastuzumab group compared to the non-trastuzumab group. According to the 
conclusion of Poncet et al, the strategy of adding trastuzumab to paclitaxel therapy seems to be 
affordable from the perspective of a French health care system. To obtain an equivalent mean cost-
effectiveness ratio in both groups, the threshold analysis evaluated the costs of a trastuzumab flask at 
432€ ($635) instead of the 626€ ($920) paid during 2002.  
The study by Hornberger et al assessed the cost-effectiveness of first-line trastuzumab treatment of 
MBC HER-2+ patients (trastuzumab+ paclitaxel vs. paclitaxel)[36]. Patients with progressing cancer 
were allowed to receive trastuzumab as second-line treatment (75% in paclitaxel group, 47% in 
trastuzumab+ paclitaxel group). Data on response duration and overall survival derived from a 
randomized-controlled study (n=469)[6]. The model comprised the costs of chemotherapy, the rate, 
severity, and costs of adverse events, and quality of life. Clinical benefits were measured in achieved 
prolonged survival and improved QALYs. The combined therapy arm achieved a survival mean of 25.0 
months compared to 15.2 months in the paclitaxel arm. In addition to this, the trastuzumab+ paclitaxel 
treatment gained higher QALYs than the control group (12.3 QALY months vs. 6.4 QALY months, 
respectively), but also increased health care costs by £18,330 ($31,894). However, the corresponding 
ICER was assumed to be cost-effective (£37,500/QALY; $65,250/QALY) and upon the 
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recommendation of the NICE Appraisal Committee, the treatment with trastuzumab+ paclitaxel of 
MBC patients was regarded as justified.  
The majority of pharmacoeconomic studies include the projection of one specific indication. Garrison 
et al established a dynamic life-cycle model to evaluate the use of trastuzumab in multiple indication 
(adjuvant and metastatic breast cancer with a HER-2 positive expression pattern) to estimate the 
overall economic value of the agent[37]. Based on publicly available data, QALYs and direct treatment 
costs were estimated over the product life-cycle of trastuzumab during 18 years. The authors aimed at 
forecasting the volume of use of trastuzumab over the product life-cycle as well as estimating its cost-
effectiveness across early stage and metastatic breast cancer patients from a payer perspective in the 
United States. The model included costs for HER-2 testing (IHC or FISH), trastuzumab therapy until 
disease progression, supervising and treating adverse events. The assumptions of costs of 
trastuzumab treatment in MBC patients were based on current medication costs. Survival estimates 
and utility weights derived from published studies. The authors projected the number of patients 
treated with trastuzumab three times lower in MBC compared to the adjuvant setting. Accordingly, 
161,000 women with MBC would be treated during the entire modeling period. The volume of 
trastuzumab use and according costs resulted in an indication specific incremental cost-effectiveness 
ratio of $85,676 per QALY gained for MBC. The ICER for the overall life-cycle summed up to 
$35,590/QALY (ICER for early breast cancer: $26,417/QALY).  
One article examined the health economic outcome of lapatinib in HER-2 overexpressing metastatic 
breast cancer patients [38]. The life-long Markov model compromised information on clinical 
effectiveness from results of two randomized controlled trials of lapatinib (EGF100151, EGF20002 
[39]). Published literature was used to gather information on health state utilities, direct and indirect 
costs of the therapy, primary adverse events, laboratory tests and costs of disease progression. The 
model took the perspective of the US societal perspective. Adding lapatinib to capecitabine therapy 
yielded additional costs of $19,630 and 0.12 QALYs. The corresponding ICER resulted in 
$166,113/QALY gained. The sensitivity analyses revealed lower probability of 2% to reach an ICER 
below $150,000/QALY. Hence, the willingness-to-pay threshold is most probably not reachable.  
The only cost-effectiveness study available with respect to bevacizumab in the first-line treatment of 
metastatic breast cancer was published by Dedes et al[40]. The study group analyzed the economic 
outcomes of bevacizumab plus paclitaxel versus paclitaxel mono-therapy in HER-2 negative MBC 
patients. Study design, progression and survival data were based on a randomized clinical trial[15]. By 
the help of a Markov model, cost-effectiveness expressed as costs per QALY was assessed. Costs 
data covered direct costs of chemotherapy treatment, most important adverse events, laboratory tests 
and disease progression. No indirect costs were taken into account. Utilities derived from published 
literature. The combined therapy of paclitaxel + bevacizumab summed up to additional per patient 
costs of €40,369 in combination with a gain of 0.21 QALYs. Consequentially, the incremental cost-
effectiveness ratio resulted in 189,427€/QALY ($278,458/QALY). The subgroup analysis showed an 
increasing ICER with age. Due to the fact of an improved benefit in efficacy, the ICER of the younger 
population (27-49 years old, ICER: 152,823€/QALY ($224,650/QALY)), was considerably lower 
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compared with the older population (65-85 years of age, ICER: 1,226,615€/QALY ($1,803,124/QALY). 
The impact of statistical uncertainties around the main input variables were assessed by one-way and 
probabilistic sensitivity analyses. By varying time to progression in the paclitaxel + bevacizumab 
group, this treatment strategy was dominated. The variation of time to progression and time from 
progression to death (paclitaxel arm) showed a further considerable influence in sensitivity analysis. In 
conclusion, the authors believe that MBC treatment with additional bevacizumab to paclitaxel is 
expensive in comparison with a willingness-to-pay of €60,000 ($88,200) per QALY gained. 
Quality assessment of key modeling issues  
Several factors may have an influence on the cost-effectiveness ratio including funding source, input 
parameters, under-reporting and the quality of the data integrated in the model. 
Input parameters 
It is therefore of paramount importance to include reliable input parameters in a model. Some articles 
mentioned in their study limitations the problem of including data from a small trial sample size. Some 
few articles were based on data from abstracts, which is probably not the best way to include reliable 
information. Several trials have been powered to show significant results in regard to clinical response 
or progression free survival, but not in terms of overall survival. Hence, those trials may identify 
significant improvements in primary endpoints, but the gain in survival remain non-significant. 
Conducting cost-effectiveness analyses based on such results are justified, as long as probabilistic 
sensitivity analyses are performed to assess the impact of model assumptions not principally related to 
statistical uncertainties.  
Sensitivity analyses 
Sensitivity analyses are usually carried out in order to estimate the influence of the statistical 
uncertainties around the model inputs. All studies have performed sensitivity analyses, but there are 
major differences with respect to their quality. Most studies conducted deterministic sensitivity 
analyses to assess the robustness of the base case by varying variables with a direct impact on 
incremental cost within a certain range (e.g. +/- 30%). Clearly described probabilistic sensitivity 
analyses have been found in three articles. One article used the bootstrapping concept, which differs 
from probabilistic sensitivity analyses by drawing observations from a data set rather than taking 
random points in a distribution. However, several studies did not mentioned how the sensitivity 
analyses were performed neither what parameter have been included. The robustness of the study 
results can only be shown if sensitivity analyses have taken all variables into account, especially those 
with a potential impact on the cost-effectiveness ratio. Critical components in a sensitivity analysis 
were prices and quantities, functional relationships, health related quality of life measure and discount 
rates.  
Perspective of the analysis  
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Most studies analyzed have taken the health system perspective (77%). These analyses do not take 
into account indirect costs, although improved cancer survival enhances the overall social surplus 
(improved labor force potential). However, a huge percentage of breast cancer patients is of working 
age. Given this, the potential of indirect cost savings and gain in productivity could be considerable 
and should not be disregarded. Only two articles have taken the societal perspective. There, not only 
direct and non-direct medical costs but also indirect costs have been included.  
Influence of the cost-effectiveness ratio 
As shown in this review, the cost-effectiveness of trastuzumab was mainly influenced by factors such 
as drug cost of trastuzumab, outpatient costs as well as administration costs. The expenditures for 
administration can be influenced by switching from a weekly administration interval to a 3-weekly 
schedule. However, as long as the drug intensity remains stable, no improvement in the cost-
effectiveness ratio seems to be feasible[33]. From the patient's point of view, a 3-week schedule may 
yield an enhancement in its quality of life. However, the weekly administration of trastuzumab has 
been shown as superior compared to the 3-weekly course in terms of median progression-free survival 
(13.4 month vs. 8.8 months, respectively)[41]. Among conventional chemotherapies, only nab-
paclitaxel was studied for different administration schedules. Weekly administration of nab-paclitaxel 
was associated with more total costs per patient than 3-weekly administration but the improved clinical 
benefit for the weekly schedule offset these costs.  
The drug cost itself was found to be a further variable boosting the economic analysis, especially in 
the case of trastuzumab[33, 35]. By lowering the cost of a trastuzumab flask by about 200€ ($294), the 
mean costs per life year gained would equal the ICER achieved by conventional chemotherapy [35]. 
The standard unit of trastuzumab is a 150mg-vial. It could be argued that providing different vials 
(10mg, 50mg) could lower the costs by administering only the exact drug dosage needed.  
In addition, the duration of the treatment with trastuzumab seems to be a point of discussion. The 
duration scheme of the targeted therapy in the included studies ranged between 24 weeks (8 
cycles)[35] up to one year[34] or until disease progression[34, 35, 37]. Prolonging treatment would be 
associated with enhanced per-patient costs[42].  
Comparability of different studies 
Typically, costs-effectiveness ratios for a novel health care intervention range between $50,000/QALY 
in the United States and £30,000/QALY ($52,200/QALY) in UK [43]. Although those thresholds are 
generally regarded as acceptable, the true willingness of the society to pay for a new intervention is 
unknown. It might be reasonable to amend this threshold across higher and lower income 
countries[44]. The included analyses have been conducted in the US/Canada (38%) or Europe (62%). 
The limitation of comparing studies from various countries lies not only in striking differences in the 
cost and resources included. Nevertheless, there are different approaches and factors which have to 
be considered when using model-based cost-effectiveness analyses across different geographic 
regions[45]. For the adjuvant treatment with trastuzumab, Essers et al presented a possibility to 
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transfer a model-based economic study by assessing criteria and limitations of the transferability [46]. 
However, the main challenge to transfer and compare results from different studies is mainly the 
transparency of the methods. Given that several studies did not clearly mention how the economic 
model was performed (states, cycle length, software used), it is very difficult to compare the model 
results. Hence, one mayor problem to evaluate the quality of the cost-effectiveness analyses is 
underreporting.  
Role of financial funding  
Several health economic studies have been conducted by fundings provided by pharmaceutical 
companies that market the analyzed drugs [25, 32, 37, 47, 48]. Some others did not declare conflict of 
interest or funding and had no author affiliated with a pharmaceutical company [21, 23, 33-35, 38, 40]. 
Although pharmaceutical company sponsorship has not been found to bias individual health economic 
studies, it has been reported that it is associated with reduced likelihood of reporting unfavorable 
results[49]. This suggests that pharmaceutical sponsored studies are less likely to publish negative 
results. In fact, among the economic analyses reviewed in this article that reported negative or 
borderline results regarding cost-effectiveness ratios were conducted and published by independent 
research groups[33, 38, 40].  
Discussion  
During recent years, many studies addressing the issue of cost and effectiveness of various new 
regimens for metastatic breast cancer have been published. Developments in the understanding of the 
molecular pathology of breast cancer have enabled the use of targeted therapies for adjuvant and 
metastatic breast cancer. At the forefront of development among conventional chemotherapies either 
potentially more potent drugs (docetaxel, ixabepilone) or established drugs with improved drug 
delivery formulations (nab-paclitaxel) have entered clinical trials and succeeded a role in daily clinical 
practice. Therapies to target specific cellular pathways expand effective cancer drugs by a systematic 
patient selection. However, the introduction of new drugs for the therapy of cancer patients normally 
increases treatment costs. Pharmaco-economic analyses are in great demand in order to obtain a 
better understanding of the cost-benefit ratio of promising cancer drugs.  
Among the new conventional chemotherapy regimens, there are some striking differences in trial 
design and included patient populations what makes comparisons across the different cost-
effectiveness studies difficult. The role of anthracyclines for the adjuvant and metastatic (if not 
received adjuvantly) treatment of most of the breast cancer types is still not refutable. This is one of 
the main reasons that most cost effectiveness analysis focus on 2nd line therapy after either 
metastatic or adjuvant anthracycline-containing regimens. At progression or recurrence after 
anthracyclines a taxane-containing regimen offers the best response rates and is considered the 
standard of care. Despite several phase III studies conducted so far, there is still no consent on the 
best taxane-containing regimen for 2nd line chemotherapy. Docetaxel has been shown to be superior 
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to paclitaxel every 3 weeks [24], but in a separate trial paclitaxel weekly is more effective than 
paclitaxel every 3 weeks[26]. On the other hand, docetaxel every week is inferior to docetaxel every 3 
weeks[50]. Furthermore, nab-paclitaxel has been compared in a phase II trial to docetaxel and showed 
superiority[30]. While Phase II trials are not perfect venues to compare agents, docetaxel was 
outperformed with regard to overall response rate by nab-paclitaxel in this setting. Similarly, the head-
to-head comparison of nab-paclitaxel with standard paclitaxel was a comparison employing every 3 
week paclitaxel and not the more effective weekly regimen. At present, it seems reasonable to 
consider all three agents useful for metastatic breast cancer, but difficult to declare a “best” agent on 
objective grounds. Therefore, cost-effectiveness studies should not omit one of the above three 
regimens. Unfortunately, paclitaxel weekly has been included as a comparator only in two cost-
effectiveness study and resulted not only as the most efficient regimen in one of them but also as the 
most cost-effective [21].  
If economic studies are conducted with poor clinical trial data, this will result in a poor outcome of the 
cost-effectiveness studies. There is an ongoing debate, whether cost-effectiveness analyses should 
only be conducted if the difference of clinical effectiveness between two treatment strategies is 
statistically significant [51-53]. However, if such data are used in economic studies, adequate 
sensitivity analyses have to be carried out to evaluate if those input parameters have an influence on 
the base case result. Recently, Chan et al published a review on cost-effectiveness analyses of 
trastuzumab in the adjuvant setting[54]. Based on the result of the review, the authors concluded that 
trastuzumab seems to be cost-effective in this setting. Nevertheless, they claimed for further high-
quality economic studies with clinical data showing the real efficacy of trastuzumab.  
Adjuvant treatment with targeted therapies may reduce future incidence of metastatic breast cancer. In 
our review, we did not include any articles, which assess the impact of adjuvant trastuzumab treatment 
on the reduced drug usage in the future metastatic indication in those patients[55]. From a health 
economic point of view, the adjuvant and metastatic setting should be evaluated separately, since 
these are two separate decisions. If lifetime incidence projections make a distinction between newly 
diagnosed and previously diagnosed metastatic breast cancer patients, bias may occur due to 
epidemiological double-counting which leads to overestimating costs and effects of the cancer therapy 
[37]. On the other hand, most cost-effectiveness studies are based on clinical data of patients naive to 
the evaluated targeted drug. The developments in clinical practice, however, are shifting the usage of 
targeted therapies to adjuvant therapy as well. In the case of trastuzumab, for example, the patient 
population on which the cost-effectiveness analysis of Norum et al[33] is based are virtually non 
existent any more since literally all of them receive trastuzumab in the adjuvant setting. If these 
patients develop metastasis, it is not clear to which extent they will benefit from the same targeted 
treatment and neither which targeted treatment is the most appropriate. Since nowadays many new 
targeted treatments are gaining market approval for various indications in breast cancer and some of 
them are also starting to be administered adjuvantly such as in case of trastuzumab and probably 
soon for lapatinib, cost-effectiveness studies for metastatic breast cancer, according to our review, 
often do not keep pace with new clinical developments. 
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Generally, the ICER of targeted non-chemotherapeutics is higher than the rates found in the 
conventional chemotherapeutic models. Given different comparators and treatment regimens, the 
lifetime ICER for trastuzumab ranged considerably. The economic models showed some major 
differences to assess the cost-effectiveness of targeted therapies. A clear description of the economic 
model used, was only given in some few articles. The two publications focusing on bevacizumab and 
lapatinib, respectively, showed no favorable ICER. Those two studies were based on clinical trial 
results and declared clearly the model methodology, the parameters included and the analyses 
performed. Furthermore, the authors did not receive any fundings from the pharmaceutical industry.  
Cost-effectiveness thresholds vary in between countries. Usually, threshold values of $20,000, 
$50,000 or $100,000 per QALY or life year gained are applied [56]. In the metastatic setting, antibody-
based targeted therapies indicated in several studies an unfavourable cost-effectiveness ratio [33, 38, 
40]. In spite of this fact, trastuzumab has been established in clinical practice in both the adjuvant and 
metastatic disease.  
There are some limitations of this systematic review. The review excluded articles written in other 
languages than English. Furthermore, results presented at meeting (abstracts) were not included. In 
addition to that, the search was limited to the database and the keywords used. This fact might have 
omitted some cost-effectiveness analyses.  
The cost-effectiveness analyses on new therapies of metastatic breast cancer are rarely found in the 
published literature and high-quality economic models are needed. For agents like bevacizumab or 
nab-paclitaxel, the clinical benefit in terms of overall survival is still under investigation and it remains 
to be seen if these new therapies will be established in clinical practice as routine therapies. 
Conclusion 
We conducted a systematic review of cost-effectiveness studies of chemotherapy and non-
chemotherapy regimens for metastatic breast cancer. In this setting, only few studies could be 
explored both for conventional chemotherapy and targeted therapies. Different conclusions were 
given. Studies on cytotoxic agents showed mostly favorable cost-effectiveness ratios. Targeted 
therapies showed both favorable and non-favorable ratios. The cost-effectiveness ratio seems to be 
dependent on the drug price, the extend of improvement in survival rates, and an altered 
administration schedule. However, the interpretation of cost-effectiveness studies can not only be 
limited to the value of the incremental cost-effectiveness ratio achieved. Moreover, the quality of the 
data and the key modeling parameters included in the analysis have to be taken into account. 
However, in case of trastuzumab the patient population included in the cost-effectiveness analyses do 
not reflect anymore the current HER-2 positive metastatic breast cancer patients, since almost all of 
them have already received trastuzumab adjuvantly nowadays. Many health care systems will have 
problems with accepting the high cost-effectiveness ratios reached by some expensive cancer 
treatments. trastuzumab, e.g., is widely justified due to its clinical benefit. The pharmaco-economic 
decision on the management of new agents like bevacizumab or nab-paclitaxel will arise, as soon as 
enough clinical evidence is available.  
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Tables 
Table I. Cost-effectiveness analyses of conventional therapies 
Study Dranitsaris[31
] 
Maniadakis[21
] 
Reed[32] Vu[23] Benedict[25]  Verma[28] 
Year 2009 2009 2009 2008 2009 2003 
Country United 
Kingdom  
Greece  US Canada  United 
Kingdom  
Canada  
Conflict of 
interest 
Yes, 
manufacturer 
funded this 
study 
No stated Yes, 
manufacturer 
funded this 
study 
None Yes, 
manufacturer 
funded this 
study, Co-
authorship 
from 
manufacturer 
Not stated 
Management 
of cancer 
nabPac Pacw, GDoc Ixb+Cap Doc Doc Cap+Doc 
Comparators Doc PacCb Cap Pac Pac3w, Pac1w, 
nabPac3w 
Doc 
Line of therapy mostly 2nd line 
(after 
anthracyclines) 
1st line (after 
adjuvant 
anthracyclines) 
2nd – 3rd line 
(after 
anthracyclines 
and taxanes) 
2nd line (after 
anthracyclines) 
2nd line (after 
anthracyclines) 
2nd lines (after 
anthracyclines) 
Study design RCT&basic 
calculations 
RCT&basic 
calculations, 
multivariate 
regression 
Stochastic 
decision-
analytic model 
based on RCT,  
Retrospective 
population 
based 
RCT&basic 
calculations, 
Markov 
modelling 
RCT& 
population 
based study 
Population age 
(range, years) 
54  60 (27-84) 52 (25-79) 55 (26-87) NM NM 
Perspective Third-payer 
perspective 
Health care 
system 
Health care 
system 
Health care 
system 
Health care 
system 
Health care 
system 
Outcome 
measure 
LYG QALY QALY LYG QALY LYG 
Time horizon Life time 34 months Life time Life time 10-year 
horizon 
Life time 
Overall mean 
cost results 
(per patient) 
nabPac100mg/
m2:  
$26,787 
 
nabPac 
150mg/m2: 
$47,366 
 
nabPac300mg/
m2: $27,508 
 
Doc: $22,486 
PacCb : 
$30,132 
 
GDoc: $28,434 
 
Pacw: $30,250 
Ixb+Cap : 
$60,900  
 
Cap: $30,000 
Doc: $9,441  
 
Pac: $2,944  
Doc: $30,139  
 
Pac3w: 
$23,144 
 
Pac1w: 
$27,793 
 
nabPac: 
$24,562 
Cap+Doc: 
$13,659 
 
Doc: $12,833 
Incremental 
cost 
nabPac100mg/
m2: $4,301 
 
nabPac 
150mg/m2: 
$24,880 
 
nabPac300mg/
m2: $5,022 
Pacw vs 
PacCb: $118 
 
Pacw vs GDoc: 
$1,816 
 
PacCb vs 
GDoc: $1,698 
$ 30,900 $6,497 to Pac3w: 
$6,995 
 
to Pac1w: 
$2,346 
 
to nabPac: 
$5,577 
$826 
Discount rate NM 3.5% 3% no 3.5%  no 
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Outcome 
results  
(unit) 
nabPac100mg/
m2: 12.8 
progression-
free months  
 
nabPac 
150mg/m2: 
12.9 
progression-
free months 
 
nabPac300mg/
m2: 11.0 
progression-
free months 
 
Doc: 7.5 
progression-
free months 
Pacw: 41 
(months) 
 
PacCb: 29.9 
(months) 
 
GDoc: 26.9 
(months) 
Ixb+Cap: 1,01 
years 
Cap: 0.84 
years 
Pac: 8.3 
months 
Doc: 10.9 
months 
Doc: 1.18 
years 
 
Pac3w: 0.85 
years 
 
Pac1w: 0.89 
years 
 
nabPac: 0.96 
years 
Cap+Doc:  
Incremental 
effect 
nabPac100mg/
m2: 5.3 months  
 
nabPac 
150mg/m2: 5.4 
months 
 
nabPac300mg/
m2: 3.5 months 
  32 quality 
adjusted days 
2.6 months to Pac3w: 0.33 
years 
 
to Pac1w: 0.29 
years 
 
to nabPac: 
0.22 
3 months 
Cost-
effectiveness 
result: ICER 
(Base case) 
nabPac100mg/
m2: $9,744 per 
PF years 
gained  
 
nabPac 
150mg/m2: 
$37,932 per 
PF years 
 
nabPac300mg/
m2: $17,226 
per PF years 
gained 
Pacw vs 
PacCb : 
dominance 
 
Pacw vs GDoc: 
$5,286 per 
QALY 
 
PacCb vs 
GDOC: 
$10,969 per 
QALY 
$359,000 per 
QALY 
$30,337 per 
LYG 
$20, 936 per 
QALY to 
Pac3w 
 
$7,974 per 
QALY to 
Pac1w 
 
$25,568 per 
QALY to 
nabPac 
$3,691 per 
LYG 
Results of 
sensitivity 
analysis  
Results robust Results robust Univariate 
sensitivity 
analyses/ 
Monte Carlos 
simulation; 
>$150,000 
Univariate 
sensitivity 
analyses: 
$13,972-  
$91,724 
Probabilistic 
sensitivity 
analysis:  
Cost ratio 
remains < 
$34,800 
Univariate 
sensitivity 
analyses: 
Results robust  
Authors 
conclusion 
nabPac is 
reasonable 
alternative to 
docetaxel 
Pw effective 
and cost-
effective 
regimen 
Ixb more 
expensive than 
other regimens 
Doc is more 
effecitive than 
Pac and may 
considered 
cost-effective 
Doc is cost-
effective 
compared to 
Pac1w, 3w and 
nabPac 
Cap+Doc is 
cost-effective 
Cap: capecitabine, Doc: docetaxel, Pac: paclitaxel, Pacw: paclitaxel weekly, nabPac: nanoparticle albumin-bound paclitaxel, Cb: 
carboplatin G: gemcitabine, Ixb: ixabepilone,  
LYG: life years gained, RCT; randomized controlled trial; NM: not mentioned; QALY: quality-adjusted life years gained.  
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Table II. Cost-effectiveness analyses of targeted therapies 
 
Study  Norum[33] Perez-
Ellis[34] 
Poncet[35] Hornberger[
48] 
Garrison[37] Dedes[40] Le[38] 
Year  2005*  2002*  2002*   2002** 2009**  2008*  2007* 
Country  Norway  France  France  UK USA  Switzerland  USA 
Conflicts of 
interest  
Not stated   Not stated 
(French 
Ministry of 
Health/ 
French 
League 
against 
Cancer 
funded study)  
Not stated 
(French 
Ministry of 
Health 
funded study)  
Not stated 
(Co-
authorship 
from 
manufacturer
) 
 Not stated 
(Unrestricted 
grant from 
manufacturer
)  
None  None 
Management 
of cancer  
T + Doc, AC 
or P  
T or T+Tax  T + Pac  T + Pac  T + Pac Pac + Bev  L + C 
Comparators  SC (Doc, AC 
or Pac)  
SC (Tax 
and/or A-
based)  
SC (Doc or 
Doc+Epi) 
Pac  Pac Pac weekly C 
Line of 
therapy  
  1st 1st line 1st line, 2nd 
line (T only 
after 
progression)  
1st line 1st line 2nd line 
Study design  RCT 
(literature) & 
basic 
calculations  
Before-and-
after design 
study & 
bootstrapping 
method  
Open 
controlled 
prospective 
study & basic 
calculations  
RCT & 
statistical 
matching 
methods/ 
Gompertz 
function  
Dynamic life-
cycle 
modeling  
Markov 
modelling 
based on 
RCT 
Markov 
modelling 
based on 
RCT 
Population 
age  
(mean, 
range, in 
years)  
T: 25-80  
SC: 24-79  
T: 51 (27-73)  
SC: 55 (26-
75)  
51 (30-77)  NM  Five age 
groups (<21, 
21-29, 40-54, 
55-65, >65)  
27-85  53 
Perspective  Third party 
payer  
Payer 
perspective 
Hospital 
perspective 
(France) 
UK National 
Health 
Service  
Payer and 
Social 
perspective  
Payer 
perspective 
Societal 
perspective 
Outcome 
measure  
LYG  LYG  LYG  QALY 
(months)  
QALY  QALY  QALY 
Time horizon  Life time  Life time (or 
until date of 
patients last 
news)  
Life time  5 years 18 years  Life time  Life time 
Overall mean 
cost results 
(per patient)  
T: $64,968 T: $58,222 
 
SC: $18,809 
T+Pac: 
$48,908  
 
SC: $16,598 
T+Pac: 
$50,373  
 
Pac: $18,479 
T+SC: 
$87,728  
 
SC: $40,000 
Pac+Bev:  
$101,492 
 
Pac: $42,149 
L + C: 
66,499$ 
 
C: 46,869$ 
Incremental 
cost  
   $39,415  $32,310  $31,894 $47728 $59,342  19,630$ 
Discount rate  5% (only for 
benefits)  
NM  NM NM  3%  No  3% 
Treatment 
duration  
40 weeks (36 
doses T)  
T for max. 
one year or 
until disease 
progression  
24 weeks (8 
cycles) or 
until disease 
progression/ 
death  
NM  Until disease 
progression  
Pac+Bev: 7.1 
months 
(followed by 
3 month Bev-
monotherapy
) 
 
Pac: 5.1 
months  
NM 
Outcome 
results  
(unit)  
T: 25.8-30.5 
months  
 
T: 37.02 
months  
 
T+Pac: 2.4 
LYG 
 
T+Pac: 12.3 
QALY-
months   
T+SC: 1.26 
QALYs  
 
Pac+BEV: 
0.90 QALYs  
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SC: 21.1 
months  
SC: 18.98 
months  
SC: 0.97 
LYG 
 
Pac: 6.4 
QALY-
months  
SC: 0.70 
QALYs 
Pac: 0.69 
QALYs 
Incremental 
effect  
3.7-8.4 
months = 
0.3-0.7 LYG  
18.04 months  1.43 LYG  5.9 QALY-
months = 
0.49 QALY  
0.56 QALY  0.21 QALYs  0.12 QALYs 
Cost-
effectiveness 
result: ICER 
(base case)  
$101,742-  
$238,753 per 
LYG  
$40,413 per 
LYG  
$22,594 per 
LYG  
$65,250 per 
QALY  
$85,676 per 
QALY  
$278,458 per 
QALY  
$166,113 per 
QALY;  
$120,184 per 
LYG 
Results of 
sensitivity 
analysis  
Results 
sensitive to 
reduced drug 
cost and 
further 
improvement 
in survival  
Cost ratio 
remains  
>$11,760 per 
LYG and  
< $29,400 
per LYG 
Threshold 
analysis: 
trastuzumab 
flask should 
be $634 to 
achieve an 
equivalent 
ICER in both 
groups  
Montecarlo 
simulation to 
assess 
distribution of 
cost-
effectiveness  
Deterministic 
sensitivity 
analysis: 
ICER ranged 
from $21,210 
to $52,842 
One-way and 
probabilistic 
sensitivity 
analysis:  
WTP of 
$88,200 was 
never 
reached  
One-way and 
probabilistic 
sensitivity 
analysis(  
95% 
confident 
limits): ICER 
$158,000-
$215,000 per 
QALY 
Authors 
conclusion  
T not cost-
effective in 
MBC  
Despite huge 
unit price, T 
should be 
considered 
as cost-
effective 
treatment for 
MBC patients  
Additional 
costs seem 
affordable 
and justified 
the use for 
HER2+ 
patients  
First-line 
treatment 
with T+Pac 
increases 
overall 
survival and 
QALYs. This 
approach is 
cost-effective  
Average 
ICER can 
increase or 
decrease for 
different 
indications 
during the 
life-cycle of a 
compound  
Addition of 
Bev is 
expensive 
given QALYs 
gained  
Addition of L 
to C 
treatment is 
not clearly 
cost-effective  
A: Anthracycline; AC: Anthracycline+Cyclophosphamide; BEV: bevacizumab; C: capecitabine; Doc: Docetaxel; Epi: Epirubicine; 
L: Lapatinib; Pac: paclitaxel; SC: standard chemotherapy; Tax: taxane; T: trastuzumab; V: Vinorelbine 
LYG: life year gained; NM: not mentioned; OS: overall survival; RCT; randomized controlled trial; WTP: willingness to pay; * 
year of monetary value; ** year of publication 
 
 
 
